IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDEAYA Biosciences (Nasdaq: IDYA) announced that three darovasertib abstracts and one IDE849 abstract have been accepted for poster presentation at the ESMO 2026 Congress, to be held October 23–27, 2026, in Madrid, Spain.

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) announced that three darovasertib abstracts and one IDE849 abstract have been accepted for poster presentation at the ESMO 2026 Congress, to be held October 23–27, 2026, in Madrid, Spain.

The company will present data updates from multiple ongoing uveal melanoma trials, including the registrational Phase 2/3 OptimUM-02 study in HLA*A2:01‑negative metastatic uveal melanoma, the Phase 2 OptimUM-01 study in HLA*A2:01‑positive metastatic uveal melanoma, and the Phase 2 OptimUM-09 neoadjuvant study in primary uveal melanoma. IDEAYA’s partner Hengrui Pharma will present long‑term results from a Phase 1 study of IDE849 (SHR‑4849), a DLL3‑targeting TOP1 antibody‑drug conjugate, in relapsed small cell lung carcinoma and other neuroendocrine carcinomas. Named academic investigators from Australia, France, the United States, and China are listed as presenting authors for each poster.

Argus Jul 17 session 1 alert

+0.22% close to close 1.33K volume Open Argus

Details

News Market Reaction – IDYA

$3.54B Mkt Cap at Peak Alert

On Jul 17, the day this news came out, IDYA closed 0.22% above the previous close.

Data tracked by StockTitan Argus for the Jul 17 session.

Key Figures

Number of abstracts: 3 presentations Conference dates: October 23–27, 2026 OptimUM-02 phase: Phase 2/3 +5 more

Number of abstracts

3 presentations

ESMO 2026 meeting for IDEAYA clinical programs

Conference dates

October 23–27, 2026

ESMO 2026 Congress in Madrid, Spain

OptimUM-02 phase

Phase 2/3

Registrational trial in HLA*A2:01‑negative metastatic uveal melanoma

OptimUM-01 phase

Phase 2

Trial in HLA*A2:01‑positive metastatic uveal melanoma

OptimUM-09 phase

Phase 2

Neoadjuvant trial in primary uveal melanoma

IDE849 trial phase

Phase 1

Study in relapsed SCLC and other NECs conducted in China

Poster ID – darovasertib neoadjuvant

2092P

OptimUM-09 neoadjuvant darovasertib ESMO 2026 poster

Poster ID – IDE849

3815P

IDE849 Phase 1 long‑term results ESMO 2026 poster

Historical Context

5 past events · Latest: Jun 26

5 events

1. Jun 26

   Equity compensation grants

   24h Move

   +1.2%

   Announcement of stock option inducement grants to newly hired employees.

2. Jun 17

   Leadership change

   24h Move

   +2.3%

   Board elects Yujiro S. Hata as Chairman alongside existing CEO role.

3. Jun 15

   Clinical trial initiation

   24h Move

   +4.3%

   First patient enrolled in Phase 1/2 IDE892 and IDE397 combo trial.

4. Jun 10

   Equity offering closing

   24h Move

   +4.5%

   Closing of public offering generating approximately $345 million gross proceeds.

5. Jun 08

   Equity offering pricing

   24h Move

   -7.6%

   Pricing of $300 million common stock and pre‑funded warrant offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neoadjuvant, registrational, adc, dll3, +2 more

6 terms

neoadjuvant medical

"the neoadjuvant setting of primary uveal melanoma"

"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.

registrational medical

"including the registrational Phase 2/3 OptimUM-02 trial"

Used as an adjective, 'registrational' describes data, studies, or trials designed specifically to convince health regulators to approve a drug, device, or treatment. Investors care because successful registrational results are the most direct path to market authorization and revenue; think of them as the final exam or blueprint that regulators use to decide whether a product can be sold widely, so passing them can materially change a company’s value.

adc medical

"IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

dll3 medical

"an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung"

DLL3 is a protein found on the surface of some cells that helps control how cells communicate and develop; in certain cancers it becomes much more common on tumor cells than on healthy tissue. Investors watch DLL3 because it can serve as a visible target or marker for drugs and diagnostics—like a unique flag on bad cells—so therapies or tests that successfully exploit DLL3 can drive clinical progress, licensing deals, and potential future revenue.

hla*a2:01 medical

"trial in HLA*A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial"

HLA-A*02:01 is a specific version of a human leukocyte antigen (HLA) class I protein that helps the immune system display bits of proteins from inside cells to T cells. Like a unique lock on a cell surface that fits certain immune “keys,” this allele determines which protein fragments are shown and therefore which immune responses are triggered. It matters to investors because its presence affects vaccine and immunotherapy effectiveness, patient selection for trials, and market size for targeted treatments.

sclc medical

"study of IDE849 (SHR-4849) being conducted in China in patients with small cell lung carcinoma (SCLC)"

SCLC stands for small cell lung cancer, an aggressive form of lung cancer that grows and spreads quickly, often requiring urgent treatment. It matters to investors because progress or setbacks in new drugs, trial results, or regulatory approvals can rapidly change a biotech or pharmaceutical company’s prospects—like a fast-moving wildfire that makes the value of firefighting tools (treatments) much more or less important. Clinical outcomes, approval decisions, and market access directly affect potential revenue and company valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncology (ESMO) meeting, taking place on October 23-27 in Madrid, Spain. The presentations will feature data updates from across IDEAYA's clinical pipeline, including multiple ongoing trials of darovasertib in uveal melanoma, including the registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial in HLA*A2:01-positive mUM, and the Phase 2 OptimUM-09 trial in the neoadjuvant setting of primary uveal melanoma. IDEAYA's partner, Hengrui Pharma, will also present clinical trial results from their Phase 1 study of IDE849 (SHR-4849) being conducted in China in patients with small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs).

"We're excited to showcase the breadth of our pipeline progress at this year's ESMO Congress. Additional data from our ongoing trials in both metastatic and neoadjuvant uveal melanoma, namely OptimUM-02, OptimUM-01 and OptimUM-09, bolster our conviction in the potential of darovasertib to become an important new treatment option across the uveal melanoma patient journey. We also hope to highlight the potential best-in-class profile of IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs, where monotherapy and combination trials are ongoing and the program's first registrational trial is targeted to initiate by year-end by partner Hengrui in China and in our regions, including the US," said Dr. Darrin Beaupre, Chief Medical Officer, IDEAYA Biosciences.

IDEAYA Presentations:

2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology, Alfred Hospital, and Department of Cancer Medicine, Monash University, Melbourne, Australia

2104P (Poster Presentation); Darovasertib with Crizotinib vs Investigator's Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma (OptimUM-02): A Subgroup Analysis. Presenting Author - Sophie Piperno-Neumann, MD, PhD, Institute Curie Research University, Paris, France 

2086P (Poster Presentation); Darovasertib and Crizotinib for HLA-A*02–Positive Metastatic Uveal Melanoma: Results from the Phase 2 OptimUM-01 Study. Presenting Author - Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, Tennessee, United States

Hengrui Presentation:

3815P (Poster Presentation); SHR-4849 (IDE849), an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs): long-term results from the Phase 1 study. Presenting Author – Haifeng Liu, PhD, Professor, Clinical Research Ward, Jilin Cancer Hospital, Changchun, China

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. 

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to IDEAYA's expectations, beliefs and plans regarding its clinical development programs, including the potential therapeutic benefits, clinical profile, and differentiating characteristics of darovasertib, IDE849, IDE892 and IDE397; the timing conduct and anticipated results of ongoing and planned clinical trials, including anticipated initiation of registrational trials; the potential of darovasertib to become an important new treatment option across the uveal melanoma treatment paradigm; the potential best-in-class profile of IDE849; the anticipated future growth of IDEAYA's pipeline and portfolio; the expected presentation and content of clinical data at the 2026 ESMO Congress; the activities and expected performance of IDEAYA's collaboration partners, including Hengrui Pharma; and the potential of IDEAYA's product candidates to address unmet medical needs. Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, regulatory activities, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials; patient enrollment rates and retention; biomarker identification, patient selection and diagnostic testing; safety, tolerability, and efficacy results; regulatory interactions and decisions; the ability to translate preclinical findings into clinical benefit; manufacturing and supply risks; competition and changes in standard of care; the timing and success of commercialization efforts; the performance of IDEAYA's collaboration partners, including their ability to conduct clinical development activities and achieve anticipated development and regulatory milestones; the outcome of collaborations and licensing arrangements; IDEAYA's ability to successfully establish, protect and defend its intellectual property; and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the Securities and Exchange Commission, including IDEAYA's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and current Reports on Form 8-K.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-clinical-programs-302828546.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ESMO 2026 presentations will IDEAYA Biosciences (IDYA) feature for darovasertib?

IDEAYA Biosciences will present three darovasertib poster abstracts at ESMO 2026 covering OptimUM-09, OptimUM-02, and OptimUM-01. According to IDEAYA, these include neoadjuvant primary uveal melanoma data and subgroup and Phase 2 results in HLA-A2–negative and HLA-A*02–positive metastatic uveal melanoma.

Which clinical trials of darovasertib in uveal melanoma are included in the IDEAYA (IDYA) ESMO 2026 posters?

The ESMO 2026 posters include OptimUM-09 in neoadjuvant primary uveal melanoma, OptimUM-02 in HLA*A2:01-negative metastatic uveal melanoma, and OptimUM-01 in HLA*A*02-positive metastatic uveal melanoma. According to IDEAYA, these ongoing trials span both metastatic and neoadjuvant treatment settings.

What is IDE849 (SHR-4849) and what data will be presented at ESMO 2026 for IDEAYA (IDYA)?

IDE849 (SHR-4849) is a DLL3-targeting TOP1 antibody-drug conjugate being developed with Hengrui Pharma. According to IDEAYA, Hengrui will present long-term Phase 1 results in relapsed small cell lung carcinoma and other neuroendocrine carcinomas at ESMO 2026 in Madrid.

When and where will the IDEAYA Biosciences (IDYA) ESMO 2026 presentations take place?

The IDEAYA and Hengrui posters will be presented during the European Society of Medical Oncology (ESMO) 2026 Congress. According to IDEAYA, the meeting will occur from October 23–27, 2026, in Madrid, Spain, featuring multiple oncology abstracts.

Who are the presenting authors for the IDEAYA (IDYA) darovasertib posters at ESMO 2026?

According to IDEAYA, the darovasertib posters will be presented by Mark Shackleton in Australia, Sophie Piperno-Neumann in France, and Meredith McKean in the United States. Each leads a poster on OptimUM-09, OptimUM-02 subgroup analysis, and OptimUM-01 results, respectively.

Which partner is collaborating with IDEAYA (IDYA) on IDE849 and what will they present at ESMO 2026?

IDEAYA’s partner for IDE849 is Hengrui Pharma, which is running a Phase 1 trial in China. According to IDEAYA, Hengrui will present long-term results in relapsed small cell lung carcinoma and other neuroendocrine carcinomas, with Haifeng Liu listed as presenting author.